vimarsana.com

Latest Breaking News On - Pfizer rare disease research unit - Page 1 : vimarsana.com

Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors

23.01.2024 - CELEBRATION, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Alvin Shih, MD, MBA, to the Company’s Board of Directors . Seite 1

United statesEli lillyUniversity of alabama school medicinePfizer rare disease research unitRetrophin incMckinsey companyHead of researchVanderbilt universityL ek consultingKellogg school of management at northwestern universityZevra boardChief operating officerRare disease researchCatamaran therapeuticsDisarm therapeuticsEnzyvant therapeutics

New Advancement Toward The First Primary Endpoint Qualification Of A Digital Endpoint For Duchenne

Current methods for assessing ambulatory function in patients with Duchenne muscular dystrophy do not fully reflect how they experience DMD in their.

Region flamandeBruxelles capitaleFrance generalRobert debrRoxana donisa dreghiciLaurent servaisCarl morrisDonisa dreghiciHead of clinical developmentLouvain medical schoolNovo nordiskFranklin pierce collegeUniversity of medicineDepartment of physiologyEuropean medicines agencyInstitute of myology

Defining Meaningful Outcomes In Gene Therapy Trials For Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy, is an X-linked recessive disease that affects approximately one in.

Roxana donisa dreghiciPatrick gonzalezCarl morrisCarla morrisJ patrick gonzalezDalle pazzeUniversity of medicineFranklin pierce collegeSyracuse universityBoston university school of medicineDepartment of physiologyResearch unitPfizer rare disease research unitRutgers universityEuropean medicines agencyUniversity of pennsylvania

Pfizer, Voyager Therapeutics ink USD 630 million gene therapy deal

Under the terms of the agreement, Pfizer will have the right to evaluate novel capsids selected for central nervous system and cardiac tropisms from Voyager s TRACER platform and to exercise options.

United statesTseng chengMichael higginsPfizer rare disease research unitMeeting of the american society geneTropism redirectionCell type specific expressionSenior vice presidentChief scientific officerRare disease researchAnnual meetingAmerican societyCell therapyTracer platformVoyager therapeuticsGene therapy

Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million | Rothwell, Figg, Ernst & Manbeck, P C

On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options to license Voyager’s adeno-associated virus (AAV).

United statesTseng chengPfizer rare disease research unitVoyager therapeuticsTropism redirectionCell type specific expressionSenior vice presidentChief scientific officerRare disease research

vimarsana © 2020. All Rights Reserved.